Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

William J. Sandborn, William J. Tremaine, Kenneth P. Offord, George M. Lawson, Bret Thomas Petersen, Kenneth P. Batts, Ivana T Croghan, Lowell C. Dale, Darrell R. Schroeder, Richard D. Hurt

Research output: Contribution to journalArticle

224 Citations (Scopus)

Abstract

Background: Ulcerative colitis is predominantly a disease of nonsmokers. Transdermal nicotine may help control clinical manifestations of this condition. Objective: To determine the efficacy of transdermal nicotine for controlling clinical disease activity in active ulcerative colitis. Design: Randomized, double-blind, placebo-controlled, single-center clinical trial. Setting: Multispecialty group serving as an academic tertiary referral center. Patients: 64 nonsmoking patients with mildly to moderately active ulcerative colitis despite the use of medication. Intervention: Patients were stratified on the basis of smoking history, extent of disease, and concomitant medical therapy. After stratification, patients were randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated dose (11 mg for 1 week and then ≤22 mg for 3 weeks) or placebo (n = 33). Measurements: Clinical features were assessed at baseline and 4 weeks by endoscopy, physician assessment, and a patient diary of daily symptoms. Serum concentrations of nicotine were determined by using gas chromatography and mass spectrometry, and plasma concentrations of cotinine were measured by using high-performance liquid chromatography. Results: At 4 weeks, 12 of 31 patients (39%) who received nicotine showed clinical improvement compared with 3 of 33 patients (9%) who received placebo (P = 0.007). Four patients receiving nicotine discontinued therapy because of side effects (contact dermatitis [n = 2], nausea [n = 1], and acute pancreatitis [n = 1]). At week 4, the nicotine group had a mean (±SD) trough serum nicotine concentration of 11.3 ± 8.4 ng/mL and a mean trough plasma cotinine concentration of 192 ± 95 ng/mL. Conclusions: Transdermal nicotine administered at the highest tolerated dosage (≤22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)364-371
Number of pages8
JournalAnnals of Internal Medicine
Volume126
Issue number5
StatePublished - 1997

Fingerprint

Nicotine
Ulcerative Colitis
Placebos
Cotinine
Contact Dermatitis
Serum
Tertiary Care Centers
Pancreatitis
Gas Chromatography-Mass Spectrometry
Nausea
Endoscopy
Therapeutics
Smoking
History
High Pressure Liquid Chromatography
Clinical Trials
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sandborn, W. J., Tremaine, W. J., Offord, K. P., Lawson, G. M., Petersen, B. T., Batts, K. P., ... Hurt, R. D. (1997). Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 126(5), 364-371.

Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. / Sandborn, William J.; Tremaine, William J.; Offord, Kenneth P.; Lawson, George M.; Petersen, Bret Thomas; Batts, Kenneth P.; Croghan, Ivana T; Dale, Lowell C.; Schroeder, Darrell R.; Hurt, Richard D.

In: Annals of Internal Medicine, Vol. 126, No. 5, 1997, p. 364-371.

Research output: Contribution to journalArticle

Sandborn, WJ, Tremaine, WJ, Offord, KP, Lawson, GM, Petersen, BT, Batts, KP, Croghan, IT, Dale, LC, Schroeder, DR & Hurt, RD 1997, 'Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial', Annals of Internal Medicine, vol. 126, no. 5, pp. 364-371.
Sandborn, William J. ; Tremaine, William J. ; Offord, Kenneth P. ; Lawson, George M. ; Petersen, Bret Thomas ; Batts, Kenneth P. ; Croghan, Ivana T ; Dale, Lowell C. ; Schroeder, Darrell R. ; Hurt, Richard D. / Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. In: Annals of Internal Medicine. 1997 ; Vol. 126, No. 5. pp. 364-371.
@article{5cfd3ccf0eaa43309b3aa0c2e467148b,
title = "Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial",
abstract = "Background: Ulcerative colitis is predominantly a disease of nonsmokers. Transdermal nicotine may help control clinical manifestations of this condition. Objective: To determine the efficacy of transdermal nicotine for controlling clinical disease activity in active ulcerative colitis. Design: Randomized, double-blind, placebo-controlled, single-center clinical trial. Setting: Multispecialty group serving as an academic tertiary referral center. Patients: 64 nonsmoking patients with mildly to moderately active ulcerative colitis despite the use of medication. Intervention: Patients were stratified on the basis of smoking history, extent of disease, and concomitant medical therapy. After stratification, patients were randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated dose (11 mg for 1 week and then ≤22 mg for 3 weeks) or placebo (n = 33). Measurements: Clinical features were assessed at baseline and 4 weeks by endoscopy, physician assessment, and a patient diary of daily symptoms. Serum concentrations of nicotine were determined by using gas chromatography and mass spectrometry, and plasma concentrations of cotinine were measured by using high-performance liquid chromatography. Results: At 4 weeks, 12 of 31 patients (39{\%}) who received nicotine showed clinical improvement compared with 3 of 33 patients (9{\%}) who received placebo (P = 0.007). Four patients receiving nicotine discontinued therapy because of side effects (contact dermatitis [n = 2], nausea [n = 1], and acute pancreatitis [n = 1]). At week 4, the nicotine group had a mean (±SD) trough serum nicotine concentration of 11.3 ± 8.4 ng/mL and a mean trough plasma cotinine concentration of 192 ± 95 ng/mL. Conclusions: Transdermal nicotine administered at the highest tolerated dosage (≤22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.",
author = "Sandborn, {William J.} and Tremaine, {William J.} and Offord, {Kenneth P.} and Lawson, {George M.} and Petersen, {Bret Thomas} and Batts, {Kenneth P.} and Croghan, {Ivana T} and Dale, {Lowell C.} and Schroeder, {Darrell R.} and Hurt, {Richard D.}",
year = "1997",
language = "English (US)",
volume = "126",
pages = "364--371",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial

AU - Sandborn, William J.

AU - Tremaine, William J.

AU - Offord, Kenneth P.

AU - Lawson, George M.

AU - Petersen, Bret Thomas

AU - Batts, Kenneth P.

AU - Croghan, Ivana T

AU - Dale, Lowell C.

AU - Schroeder, Darrell R.

AU - Hurt, Richard D.

PY - 1997

Y1 - 1997

N2 - Background: Ulcerative colitis is predominantly a disease of nonsmokers. Transdermal nicotine may help control clinical manifestations of this condition. Objective: To determine the efficacy of transdermal nicotine for controlling clinical disease activity in active ulcerative colitis. Design: Randomized, double-blind, placebo-controlled, single-center clinical trial. Setting: Multispecialty group serving as an academic tertiary referral center. Patients: 64 nonsmoking patients with mildly to moderately active ulcerative colitis despite the use of medication. Intervention: Patients were stratified on the basis of smoking history, extent of disease, and concomitant medical therapy. After stratification, patients were randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated dose (11 mg for 1 week and then ≤22 mg for 3 weeks) or placebo (n = 33). Measurements: Clinical features were assessed at baseline and 4 weeks by endoscopy, physician assessment, and a patient diary of daily symptoms. Serum concentrations of nicotine were determined by using gas chromatography and mass spectrometry, and plasma concentrations of cotinine were measured by using high-performance liquid chromatography. Results: At 4 weeks, 12 of 31 patients (39%) who received nicotine showed clinical improvement compared with 3 of 33 patients (9%) who received placebo (P = 0.007). Four patients receiving nicotine discontinued therapy because of side effects (contact dermatitis [n = 2], nausea [n = 1], and acute pancreatitis [n = 1]). At week 4, the nicotine group had a mean (±SD) trough serum nicotine concentration of 11.3 ± 8.4 ng/mL and a mean trough plasma cotinine concentration of 192 ± 95 ng/mL. Conclusions: Transdermal nicotine administered at the highest tolerated dosage (≤22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.

AB - Background: Ulcerative colitis is predominantly a disease of nonsmokers. Transdermal nicotine may help control clinical manifestations of this condition. Objective: To determine the efficacy of transdermal nicotine for controlling clinical disease activity in active ulcerative colitis. Design: Randomized, double-blind, placebo-controlled, single-center clinical trial. Setting: Multispecialty group serving as an academic tertiary referral center. Patients: 64 nonsmoking patients with mildly to moderately active ulcerative colitis despite the use of medication. Intervention: Patients were stratified on the basis of smoking history, extent of disease, and concomitant medical therapy. After stratification, patients were randomly assigned to daily treatment with transdermal nicotine (n = 31) at the highest tolerated dose (11 mg for 1 week and then ≤22 mg for 3 weeks) or placebo (n = 33). Measurements: Clinical features were assessed at baseline and 4 weeks by endoscopy, physician assessment, and a patient diary of daily symptoms. Serum concentrations of nicotine were determined by using gas chromatography and mass spectrometry, and plasma concentrations of cotinine were measured by using high-performance liquid chromatography. Results: At 4 weeks, 12 of 31 patients (39%) who received nicotine showed clinical improvement compared with 3 of 33 patients (9%) who received placebo (P = 0.007). Four patients receiving nicotine discontinued therapy because of side effects (contact dermatitis [n = 2], nausea [n = 1], and acute pancreatitis [n = 1]). At week 4, the nicotine group had a mean (±SD) trough serum nicotine concentration of 11.3 ± 8.4 ng/mL and a mean trough plasma cotinine concentration of 192 ± 95 ng/mL. Conclusions: Transdermal nicotine administered at the highest tolerated dosage (≤22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.

UR - http://www.scopus.com/inward/record.url?scp=15644374610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15644374610&partnerID=8YFLogxK

M3 - Article

VL - 126

SP - 364

EP - 371

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -